Seroatlas · Human Serome Atlas

SLC13A5

Na(+)/citrate cotransporter

Also known as: INDY, NACT, S13A5_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q86YT5
Gene
SLC13A5
Ensembl
ENSG00000141485
Chromosome
17
Canonical length
568 aa
Protein class
Disease related genes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted membrane proteins, Transporters
Subcellular location
Nucleoplasm,Plasma membrane
Quaternary structure
Homodimer

OverviewNCBI Gene

This gene encodes a protein belonging to the solute carrier family 13 group of proteins. This family member is a sodium-dependent citrate cotransporter that may regulate metabolic processes. Mutations in this gene cause early infantile epileptic encephalopathy 25. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2014]

Canonical amino-acid sequenceUniProt

568 residues, UniProt reviewed canonical sequence.

>Q86YT5|SLC13A5
     1  MASALSYVSK FKSFVILFVT PLLLLPLVIL MPAKFVRCAY VIILMAIYWC TEVIPLAVTS
    61  LMPVLLFPLF QILDSRQVCV QYMKDTNMLF LGGLIVAVAV ERWNLHKRIA LRTLLWVGAK
   121  PARLMLGFMG VTALLSMWIS NTATTAMMVP IVEAILQQME ATSAATEAGL ELVDKGKAKE
   181  LPGSQVIFEG PTLGQQEDQE RKRLCKAMTL CICYAASIGG TATLTGTGPN VVLLGQMNEL
   241  FPDSKDLVNF ASWFAFAFPN MLVMLLFAWL WLQFVYMRFN FKKSWGCGLE SKKNEKAALK
   301  VLQEEYRKLG PLSFAEINVL ICFFLLVILW FSRDPGFMPG WLTVAWVEGE TKYVSDATVA
   361  IFVATLLFIV PSQKPKFNFR SQTEEERKTP FYPPPLLDWK VTQEKVPWGI VLLLGGGFAL
   421  AKGSEASGLS VWMGKQMEPL HAVPPAAITL ILSLLVAVFT ECTSNVATTT LFLPIFASMS
   481  RSIGLNPLYI MLPCTLSASF AFMLPVATPP NAIVFTYGHL KVADMVKTGV IMNIIGVFCV
   541  FLAVNTWGRA IFDLDHFPDW ANVTHIET

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC13A5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
11
Mean surface accessibility (rSASA)
0.26
Highest tissue expression
394 nTPM

Expression across tissuesHPA

Tissue

  • liver: 394 nTPM
  • salivary gland: 36 nTPM
  • basal ganglia: 8.4 nTPM
  • cerebral cortex: 7.7 nTPM
  • amygdala: 4.3 nTPM
  • midbrain: 3.5 nTPM

Single-cell type

  • hepatocytes: 440 nCPM
  • salivary acinar cells: 242 nCPM
  • salivary myoepithelial cells: 98 nCPM
  • astrocytes: 43 nCPM
  • bergmann glia: 29 nCPM
  • neutrophils: 13 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • hypothalamus: 12 nTPM
  • cerebral cortex: 11 nTPM
  • medulla oblongata: 9.9 nTPM
  • basal ganglia: 9.7 nTPM
  • thalamus: 9.7 nTPM
  • midbrain: 7.7 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SLC13A5.

Disease | AllUniProt

Conditions SLC13A5 is implicated in, by any mechanism.

  • Developmental and epileptic encephalopathy 25, with amelogenesis imperfecta (DEE25) MIM:615905

Disease | GeneticClinVar

62 pathogenic / likely-pathogenic of 811 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.67
gnomAD pLI
0
gnomAD missense Z
1.14
DepMap mean gene effect
-0.02
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC13A5 as an antibody target. Whether an autoantibody or antibody against SLC13A5 could matter depends on whether native SLC13A5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC13A5 is annotated at the cell surface, where native SLC13A5 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC13A5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SLC13A5. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...